Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Brief Summary

Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)

Intervention / Treatment

  • Psilocybin (DRUG)
    COMP360 Psilocybin administered under supportive conditions

Condition or Disease

  • Treatment Resistant Depression

Phase

  • Phase 3
  • Study Design

    Study type: INTERVENTIONAL
    Status: Recruiting
    Study results: No Results Available
    Enrollment: 568 (ESTIMATED)
    Allocation: Randomized
    Primary Purpose: Treatment

    Masking

    QUADRUPLE:
    • Participant
    • Care Provider
    • Investigator
    • Outcomes Assessor

    Clinical Trial Dates

    Start date: Feb 14, 2023 ACTUAL
    Primary Completion: Mar 01, 2025 ESTIMATED
    Completion Date: May 01, 2025 ESTIMATED
    Study First Posted: Feb 03, 2023 ACTUAL
    Last Updated: Sep 13, 2023

    Sponsors / Collaborators

    Lead Sponsor: COMPASS Pathways
    Lead sponsor is responsible party
    Responsible Party: N/A

    This is a phase III, international, multi-centre, randomised, parallel group, fixed repeat dose, double-blind, controlled study. The study population will include participants aged ≥18 years with TRD.

    Overall, 568 participants are to be randomised in a 2:1:1 ratio to receive COMP360 25 mg, 10 mg or 1 mg.

    The study will last up to 16 weeks including a three- to ten-week Screening Period and six-week follow-up from investigational product (IP) administration.

    In this study, the aim is to assess the efficacy of COMP360, administered with psychological support in adult participants with TRD, in improving symptoms of depression.

    Participant Groups

    • 25 mg COMP360 Psilocybin

    • 10 mg COMP360 Psilocybin

    • 1 mg COMP360 Psilocybin, active comparator

    Eligibility Criteria

    Sex: All
    Minimum Age: 18
    Age Groups: Adult / Older Adult
    Healthy Volunteers: Yes

    Key Inclusion Criteria:

    1. Aged ≥18 years at Screening
    2. Major depression without psychotic features (single or recurrent episode as informed by the Diagnostic and Statistical Manual of Mental Disorders, 5th edition \[DSM-5\])
    3. If the current major depressive episode is the participant's first lifetime episode of depression, the length of the current episode must be ≥3 months and ≤2 years at Screening
    4. MADRS total score ≥20 at Screening and Baseline to ensure at least moderate severity of depression
    5. TRD, defined as failure to respond to an adequate dose and duration of two, three, or four different pharmacological treatments for the current episode as determined through the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and using the supplementary advice on additional antidepressants not included in MGH-ATRQ
    6. At Screening, agreement to discontinue all prohibited medications

    Key Exclusion Criteria:

    1. Prior or ongoing bipolar disorder, any psychotic disorder, including schizophrenia, schizophreniform disorder, schizoaffective disorder, brief psychotic disorder (unless substance induced or due to a medical condition), antisocial personality disorder as assessed by a structured clinical interview (MINI 7.0.2)
    2. Lifetime paranoid, schizoid, schizotypal, histrionic, narcissistic personality disorder, or any ongoing serious psychiatric comorbidity based on medical history and clinical judgement
    3. Borderline personality disorder as demonstrated by medical history or the Mini International Neuropsychiatric Interview Plus (MINI plus) - borderline personality disorder module
    4. Ongoing post-traumatic stress disorder, obsessive-compulsive disorder, or anorexia nervosa as assessed by medical history and a structured clinical interview (MINI 7.0.2)
    5. Psychiatric inpatient within the past 12 months prior to Screening
    6. Use of electroconvulsive therapy, deep brain stimulation, or vagus nerve stimulation during the current depressive episode
    7. Transcranial magnetic stimulation within the past six months prior to Screening
    8. Current enrolment in a psychological therapy programme that will not remain stable for the duration of the study. Psychological therapies cannot have been initiated within 30 days prior to Screening
    9. Exposure to COMP360 psilocybin therapy prior to Screening

    This clinical trial is recruiting

    Are you interested in participating in this trial or others? We'd love to help.

    Primary Outcomes
    • Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10-item clinician rated scale measuring depression severity

    Secondary Outcomes
    • Sheehan Disability Scale (SDS) is a brief, five-item self report inventory that assesses functional impairment in work/school, social life, and family life.

    • Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10-item clinician rated scale measuring depression severity

    • Sheehan Disability Scale (SDS) is a brief, five-item self report inventory that assesses functional impairment in work/school, social life, and family life.

    More Details

    NCT Number: NCT05711940
    Other IDs: COMP 006
    Study URL: https://clinicaltrials.gov/study/NCT05711940
    Last updated: Sep 29, 2023